期刊文献+

人源抗滋养层细胞表面抗原-2基因工程抗体Fab的制备及特性分析 被引量:5

Preparation and Characterization of Human Anti-Trop-2 Engineering Antibody Fab
下载PDF
导出
摘要 应用噬菌体抗体库技术制备全人源抗滋养层细胞表面抗原-2(Trop-2)特异性Fab抗体片段.抗体库经细胞筛选和固相抗原筛选,获得特异性的阳性克隆.阳性载体经核酸序列分析后,构建工程菌,经IPTG诱导表达,SDS-PAGE和Western blot分析,呈现28ku和32ku大小的两条蛋白质条带.Fab分子经流式细胞术、细胞免疫荧光检测,结果表明,Fab能够与BxPc3细胞膜蛋白特异性结合,而与NIH3T3细胞不结合.免疫共沉淀与质谱分析结果表明,该Fab分子能够与Trop-2蛋白特异性结合.免疫组化显示,该抗体可结合胰腺癌细胞膜蛋白,在细胞培养液中加入Fab,能够抑制BxPc3细胞的生长.以上研究结果提示,该抗体有望成为胰腺癌临床影像诊断或治疗的候选分子. Fully human antibody fragment Fab that specifically binding to Trop-2 (trophoblast cell-surface antigens 2, Trop-2), was selected from phage display antibody library. Positive phage-displayed antibody clones were selected on live cell lines and immobilized protein. The purified Fab was verified by SDS-PAGE and Western blot, which showed two bands at about 28 ku and 32 ku at the expected sizes. To analyze the immunological characters of Fab for Trop-2 binding, flow cytometry, immunoprecipitation assays and mass spectrometry were set up and carried out with BxPc3 and NIH3T3 cell lines. The results demonstrated Fab could bind native Trop-2 specifically on the BxPc3 cell surface. Peptide mapping fingerprint showed that the protein which bound is Trop-2 protein. Immunohistochemistry detection illuminated Fab could bind the membrance protein of pancreatic cancer tissue. In vitro cell growth inhibition assay showed that anti-Trop-2 Fab could inhibit the Trop-2 positive cell BxPc3 growth, it illuminated that anti-Trop-2 Fab bound the Trop-2 on Trop-2 positive cell surface. For Trop-2 negative cell line NIH3T3, no significant inhibition among the different dosages of Fab. The results showed that anti-Trop-2 Fab antibody fragments could recognize Trop-2 extracellular domain in native conformation, making them as potential powerful reagents for clinical therapeutic application.
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2010年第10期1101-1107,共7页 Progress In Biochemistry and Biophysics
基金 南京市医学科技发展重点项目(ZKX09015) 南京市科技发展项目(200901083)资助~~
关键词 噬菌体抗体库 胰腺癌 人源抗Trop-2抗体 phage-displayed antibody library, pancreatic carcinoma, human anti-Trop-2 antibody fragment Fab
  • 相关文献

参考文献17

  • 1Cascinu S, Berardi R, Labianca R, et ol. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol, 2008, 9(1): 39-44.
  • 2Iacobuzio-Donahue C A, Maitra A, Shen-Ong G L, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol, 2002, 160(4): 1239-1249.
  • 3Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res, 2007, 13(11): 3356-3362.
  • 4Gamez-Varela D, Zwick-Wallasch E, Kntgen H, et al. Monoclonal antibody blockade of the human Eagl potassium channel function exerts antitumor activity. Cancer Res, 2007, 67(15): 7343-7349.
  • 5Ripani E, Sacchetti A, Corda D, et ol. Human TROP-2 is a tumor- associated calcium signal transducer. Int J Cancer, 1998, 76:671-676.
  • 6Villablanca E J, Renucci A, Sapede D, et ol. Control of cell migration in the zebrafish lateral line: implication of the gene tumour-associated calcium signal transducer, tacstd. Dev Dyn, 2006, 235(3): 1578-1588.
  • 7Guerra E, Trerotola M, Arciprete R D, etal. A bicistronic cyclin D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res, 2008, 68(19): 8113-8121.
  • 8Alberti S, Vacca G, Trerotola M, et ol. Trop-2 is a novel PKC- dependent growth-stimulator trans-membrane molecule and a metastasis marker in human cancer. Proc Amer Assoc Cancer Res,2006,47:2483.
  • 9Alberti S, Trerotola M, Vacca G, et al. Novel role of TROP2 in breast cancer growth and metastatization. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I, 2007, 25(18S): 10510.
  • 10Fong D, Spizzo G, Gostner J M, et al. TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity. Modem Pathology, 2008, 21(12): 186-191.

同被引文献51

  • 1Wan-Yee Lau,Eric C.H.Lai.Development and controversies of adjuvant therapy for pancreatic cancer[J].Hepatobiliary & Pancreatic Diseases International,2008,7(2):121-125. 被引量:5
  • 2郑媛媛.肿瘤的单抗靶向疗法在国内的研究和应用进展[J].中国肿瘤生物治疗杂志,2006,13(1):70-72. 被引量:2
  • 3朱洁(综述),王绮如(审校).单克隆抗体药物在肿瘤靶向治疗中的应用与展望[J].中国医师杂志,2007,9(7):1006-1007. 被引量:4
  • 4Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers[J], nol Cancer Ther,2008,7(2):2S0-2S5.
  • 5Flanagan RJ,Jones AL. Fab antibody fragments: some applications in clinical toxicology [J]. Drug Saf,2004,27 (14):1115-1133.
  • 6Kim EK,Choi EJ. Pathological roles of MAPK signaling pathways in human diseases [J]. Biochim Biophys Acta, 2010,1802(4) : 396-405.
  • 7Humphreys DP,Glover DJ. Therapeutic antibody produc- tion technologies:molecules,applications,expression and purification [J]. Curt Opin Drug Discov Devel,2001,4 (2):172-185.
  • 8Grossman TH, Kawasaki ES, Punreddy SR, et al. Sponta- neous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability[J]. Gene, 1998,209(1-2) : 95-103.
  • 9studier FW. Protein production by auto-induction in high density shaking cultures [J]. Protein Expr Purif., 2005,41 (1) :207-234.
  • 10D Fong,P Moser,C Krammel,et al. High expression of TROP2 correlates with poor prognosis in pancreatic can- cer[J]. Br J Cancer,2008,99(8) : 1290-1295.

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部